- CA$63.16m
- CA$78.46m
- CA$0.41m
- 28
- 13
- 57
- 24
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 228.22 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -1256.5% | ||
Financial Summary
| Year End 31st Jul | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 0.92 | 2.14 | 0.95 | 0.43 | 0.41 | n/a | n/a | -4.79% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
MedMira Inc. is a Canada-based developer and manufacturer of Rapid Vertical Flow (RVF) diagnostics. The Company's tests provide hospitals, labs, clinics and individuals with instant disease diagnosis, such as human immunodeficiency virus (HIV), syphilis, hepatitis, and SARS-CoV-2, in three steps. The Company is engaged in the business of research, development and manufacturing of rapid diagnostics and technologies. Its research is focused on specific areas of the broader diagnostics market, namely the rapid, point-of-care, and in vitro sectors. Its tests are sold globally under the REVEAL, REVEALCOVID-19, Multiplo and Miriad brands. Based on its patented Rapid Vertical Flow Technology, the Company's rapid HIV test has regulatory approvals in Canada, the United States, China and the European Union. Its manufacturing facilities are located in Halifax, Nova Scotia, Canada. It provides access to its RVF Technology for researchers, developers, and biotech companies on a license basis.
Directors
- Last Annual
- July 31st, 2024
- Last Interim
- January 31st, 2025
- Incorporated
- July 26th, 1999
- Public Since
- December 1st, 1999
- No. of Employees
- 65
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
TSX Venture Exchange- Shares in Issue
- 701,730,591
- Address
- 155 Chain Lake Dr.,, Suite 1, HALIFAX, B3S 1B3
- Web
- https://medmira.com/
- Phone
- +1 9024501588
- Auditors
- Arsenault Best Cameron Ellis
Upcoming Events for MIR
Similar to MIR
Aurora Spine
TSX Venture Exchange
CardioComm Solutions
TSX Venture Exchange
Conavi Medical
TSX Venture Exchange
Covalon Technologies
TSX Venture Exchange
EvokAI Creative Labs
TSX Venture Exchange
FAQ
What is the MedMira share price?
As of Today at 21:59 UTC, shares in MedMira are trading at CA$0.09. This share price information is delayed by 15 minutes.
How has the MedMira share price performed this year?
Shares in MedMira last closed at CA$0.09 and the price had moved by +20% over the past 365 days. In terms of relative price strength the MedMira share price has outperformed the Toronto Stock Exchange 300 Composite Index by +6.69% over the past year.
What are the analyst and broker recommendations for MedMira?
There is no consensus recommendation for this security.
Find out moreWhat is the MedMira dividend yield?
MedMira does not currently pay a dividend.
Does MedMira pay a dividend?
MedMira does not currently pay a dividend.
When does MedMira next pay dividends?
MedMira does not currently pay a dividend.
How do I buy MedMira shares?
To buy shares in MedMira you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of MedMira?
As of the previous close price of CA$0.09, shares in MedMira had a market capitalisation of CA$63.16m.
Where are MedMira shares listed?
Here are the trading details for MedMira:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: MIR
What kind of share is MedMira?
Based on an overall assessment of its quality, value and momentum MedMira is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a MedMira share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the MedMira share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like MedMira. Over the past six months, its share price has outperformed the Toronto Stock Exchange 300 Composite Index by +11.84%.
As of the last closing price of CA$0.09, shares in MedMira were trading -4.38% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the MedMira PE Ratio?
The MedMira PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.09.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of MedMira?
MedMira's management team is headed by:
- Hermes Chan - CEO
- Markus Meile - CFO
- Thomas Bergmann - IND
- Steven Cummings - IND
- Jianhe Mao - IND